MedTrace Logo

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline

NCT01435213 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-02-18

No results posted yet for this study

Summary

The purpose of this study is to validate \[11C\]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.

Conditions

  • Healthy

Interventions

DRUG

Atipamezole

Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion

DRUG

Atomoxetine

A single dose of 1.2 mg/kg of atomoxetine administered orally

DRUG

Ketamine

A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion

OTHER

Cold pressor test

30-45 min cold pressor test of the foot

DRUG

Insulin

Insulin administered as an intravenous infusion to induce hypoglycemia

DRUG

Placebo

A single dose of placebo (capsules) administered orally

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • University of Turku

    lead OTHER

Principal Investigators

  • Juha Rinne, MD, PhD · University of Turku

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435213 on ClinicalTrials.gov